UroGen Pharma Ltd.

Nasdaq URGN · Ra'Anana, Israel

Works in Oncology · Renal & urogenital · Women's health

UroGen Pharma Ltd. is a clinical trial sponsor based in Ra'Anana, Israel, listed as Nasdaq URGN. It has 3 active clinical trials with 760 planned participants, in Oncology, Renal & urogenital and Women's health. Since 2021 it has completed 4 trials and stopped 1 early.

Trial track record · since 2021

3Active trials760 planned participants
4Completed5 with results posted
1Stopped early20% of finished trials

Financials · Nasdaq URGN

Cash and equivalents
R&D expense
Net income (loss)
Cash runway

Pipeline · 3 active trials

StageTrialStatus

On the market

2 approved drug applications with a product on the market.

Questions about UroGen Pharma Ltd

See the rest of this profile

A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.

Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-22.

Approve Suite is not affiliated with UroGen Pharma Ltd..

See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.